...
首页> 外文期刊>Journal of Medical Biochemistry >Beta-Trace Protein as a Marker of Renal Dysfunction in Patients with Chronic Kidney Disease: Comparison with Other Renal Markers
【24h】

Beta-Trace Protein as a Marker of Renal Dysfunction in Patients with Chronic Kidney Disease: Comparison with Other Renal Markers

机译:Beta追踪蛋白作为慢性肾脏病患者肾功能不全的标志物:与其他肾标志物的比较

获取原文

摘要

Beta-Trace Protein as a Marker of Renal Dysfunction in Patients with Chronic Kidney Disease: Comparison with Other Renal MarkersBeta-trace protein (BTP), also known as prostaglandin D synthase, is a low-molecular-mass protein which belongs to the lipocalin protein family. It was found to be increased in the serum of patients with renal diseases. The aim of this study was to compare the clinical usefulness of serum levels of beta-trace protein for the detection of renal dysfunction in patients with chronic kidney disease (CKD) with levels of other renal markers: creatinine, cystatin C and β2-microglobulin (B2M). The study included 134 patients with a wide range of renal dysfunction that encompassed all five CKD stages. Obtained data showed that beta-trace protein highly correlated (Spearman test) with creatinine (r = 0.890), cystatin C (r = 0.904) and B2M (r = 0.933) and its levels in serum significantly increased from CKD stage 1 to 5. Furthermore, the values of glomerular filtration rate (GFR) estimated from a BTP-based formula significantly correlated with GFR calculated from creatinine-based and cystatin C-based formulas. ROC analyses showed that BTP had similar diagnostic accuracy for detection of reduced renal function in CKD stages as other renal markers, for estimated GFRs of 2. The areas under the ROC curves (AUC) for BTP, for these GFR limits, were from 0.983 to 0.917 and they were not significantly different from AUCs for other renal markers. The results of this study showed that BTP may be a useful and reliable serum marker for identifying the magnitude of renal dysfunction in patients with CKD and may have its place beside serum cystatin C and creatinine as an alternative endogenous GFR marker.
机译:β-痕量蛋白可作为慢性肾脏病患者肾功能障碍的标志物:与其他肾标志物的比较β-痕量蛋白(BTP),也称为前列腺素D合酶,是一种低分子质量蛋白,属于lipocalin蛋白家庭。发现其在肾病患者的血清中增加。这项研究的目的是比较血清β-痕量蛋白水平在检测慢性肾脏病(CKD)患者肾功能不全中的临床实用性与其他肾标志物(肌酐,半胱氨酸蛋白酶抑制剂C和β2-微球蛋白( B2M)。这项研究纳入了134名患有广泛肾功能不全的患者,涵盖了所有五个CKD阶段。获得的数据表明,β-迹蛋白与肌酐(r = 0.890),胱抑素C(r = 0.904)和B2M(r = 0.933)高度相关(Spearman检验),并且其血清水平从CKD第1阶段到第5阶段显着增加。此外,从基于BTP的公式估算出的肾小球滤过率(GFR)值与从基于肌酸酐和半胱氨酸蛋白酶抑制剂C的公式计算得出的GFR显着相关。 ROC分析显示,对于估计的GFR为2,BTP对CKD期肾功能降低的诊断准确性与其他肾标志物相似。对于这些GFR限值,BTP的ROC曲线下面积(AUC)为0.983至0.98。 0.917,它们与其他肾标志物的AUC没有显着差异。这项研究的结果表明,BTP可能是一种有用且可靠的血清标志物,可用于确定CKD患者的肾功能不全的程度,并可能在血清胱抑素C和肌酐之外作为替代性内源性GFR标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号